Related Experiment Video
Updated: Jan 3, 2026
07:04
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
1.0K
Immune checkpoint inhibitors: a promising anticancer therapy
Sima Singh1, Daniel Hassan1, Hibah M Aldawsari2
1Discipline of Pharmaceutical Sciences, College of Health Sciences, University of KwaZulu-Natal, Private Bag X54001, Durban, South Africa.
Drug Discovery Today
|November 19, 2019
Summary
Immune checkpoint inhibitors (ICIs) are transforming cancer care but face challenges like side effects and resistance. Advances in understanding the immune system and patient monitoring are improving ICI effectiveness.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Immune checkpoint inhibitors (ICIs) represent a significant advancement in cancer therapy, offering potential for durable responses.
- However, their clinical application is limited by immune-related adverse events (irAEs) and the development of therapeutic resistance.
Purpose of the Study:
- To review the current landscape of ICI therapy across various diseases.
- To discuss therapeutic outcomes and challenges associated with ICI treatment.
- To highlight biomarkers predictive of ICI response.
Main Methods:
- Literature review of current research on immune checkpoint inhibitors.
- Analysis of therapeutic outcomes and adverse events in different cancer types.
- Identification and discussion of biomarkers associated with ICI efficacy.
Main Results:
- ICIs have shown revolutionary potential in treating numerous cancers.
- Strategies including improved understanding of the immune system, disease history, treatment duration, combination therapies, biomarkers, and patient monitoring are addressing ICI limitations.
- Various biomarkers are associated with predicting patient response to ICI therapy.
Conclusions:
- ICI therapy is a rapidly evolving field with significant therapeutic potential.
- Overcoming irAEs and resistance is crucial for maximizing ICI benefits.
- Biomarker discovery and patient monitoring are key to optimizing ICI treatment strategies.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
01:30Cancer Vaccines
907
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
907
02:38Mitogens and the Cell Cycle
7.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K
02:34Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
02:50Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K